Revenue segments as reported by the company.

Waters

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative expenses

Research and development expenses

Purchased intangibles amortization

Asset impairment

Litigation provision

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services. The TA segment products and services include thermal analysis, rheometry and calorimetry instrument systems, and service sales. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Waters reports robust Q4 earnings, eyes growth through acquisitions

Waters Corporation's strong performance in Q4 2022 and full-year results, coupled with the Wyatt Technology acquisition, positions the company for continued growth.
Despite challenges in China and FX headwinds, Waters sees opportunities in pricing increases, revenue synergies from acquisitions, and growth in bioanalytical applications.

Waters Corp reports Q1 revenue growth below expectations, eyes biotech

Waters Corporation faces challenges from weaker demand in key sectors but maintains strengths in certain divisions and sustainability efforts. The acquisition of Wyatt Technology presents growth opportunities, with a focus on maintaining pricing strength and capitalizing on ongoing pharma activity.

Waters (WAT) reports robust Q2 growth, eyes Chinese market recovery

Waters Corporation delivered strong Q2 performance with 5% constant currency growth and non-GAAP EPS above expectations, driven by operational excellence and margin expansion.
While challenges persist in the China Pharma market and cautious spending trends impact growth outlook, Waters remains well-positioned for growth above market rates.
The company's strategic strengths in innovation, execution, and margin expansion, coupled with growth opportunities in key segments and regions, position it for continued success.

Waters expands margins amidst China challenges, eyes service growth

Waters Corporation navigated through challenges in China, focusing on margin expansion, cost management, and workforce optimization. Despite headwinds, the company showcased resilience, positive cash flow, and growth opportunities in service attachment rates and e-commerce sales.

Waters faces sales decline in Q4 2023, eyes PFAS market

Waters navigated a challenging Q4 2023 with sales decline and cautious Q1 2024 guidance. Despite China's struggles, the company's operational resilience and focus on sustainability are strengths. Opportunities lie in PFAS testing, e-commerce growth, and large molecule applications.

Waters Corp exceeds EPS guidance, eyes China stimulus for growth

Waters Corporation's Q1 2024 performance was solid, with a focus on margin expansion and innovation. Challenges include sales decline and concerns about revenue targets. Opportunities exist in China's pharma market stabilization and margin progression.

Waters Corporation surpasses Q2 expectations, eyes long-term growth strategies

Waters Corporation delivered strong Q2 results, exceeding expectations with resilient margins.
While facing sales declines, the company showcased operational efficiency and strategic focus.
Guidance reflects caution on ex-China markets but highlights opportunities for growth.
Strategic flexibility in debt management and product innovation position the company for long-term success.

Waters Corporation excels in Q3, eyes growth in key markets

Waters Corporation's strong Q3 performance exceeded expectations, driven by sales growth in key sectors and recurring revenue expansion.
Despite challenges like China sales decline and negative sales growth projections, the company remains optimistic about future opportunities.
With a focus on operational excellence, strategic positioning, and market confidence, Waters is poised for continued success and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genuine Parts

PBF Energy

RingCentral

One must follow rating upgrades by brokers as they have a deeper understanding of the stocks. We choose PBF Energy (PBF), Genuine Parts (GPC), RingCentral (RNG) and Waters (WAT) as these witness ratings upgrades.

4 Stocks With Upgraded Broker Ratings to Consider Right Now

MINNEAPOLIS--(BUSINESS WIRE)-- #ASMS2022--Waters Corporation unveiled new instruments, software and product enhancements at the American Society for Mass Spectrometry 2022 Annual Conference.

Waters Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

Why Is Waters (WAT) Down 6% Since Last Earnings Report?

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2022 Global Healthcare Conference in New York City on Wednesday, June 8th, 2022 at 4:30PM Eastern Standard Time. Interested investors can access the live webcast of the presentation on Waters' investor relations website at https://ir.waters.com. A replay of the webcast will be available for 30 days. About Waters Corporation

Waters Corporation Presentation at the Jefferies 2022 Global Health Care Conference

Waters Corporation (NYSE:WAT ) 2022 Investor Day Conference Call May 19, 2022 10:00 AM ET Company Participants Caspar Tudor - Head IR Dr. Udit Batra - President and CEO Jon Pratt - SVP, Waters Division Jianqing Bennett - SVP, TA Instruments Division Amol Chaubal - SVP and CFO Conference Call Participants Derik De Bruin - Bank of America Vijay Kumar - Evercore Dan Brennan - Cowen Luke Sergott - Barclays Josh Waldman - Cleveland Research Puneet Souda - SVB Leerink Patrick Donnelly - Citi Rachel Vatnsdal - JPMorgan Matt Sykes - Goldman Sachs Caspar Tudor Hello, everyone. Good morning.

Waters Corporation (WAT) CEO Dr. Udit Batra Hosts 2022 Investor Day Conference (Transcript)

Arthur J. Gallagher & Co.

One must follow rating upgrades by brokers as they have a deeper understanding of the stocks. We pick Genuine Parts (GPC), RingCentral (RNG) Waters (WAT), PBF Energy (PBF) and Arthur J.

5 Stocks to Bet on Right Now on Upgraded Broker Ratings

MILFORD, Mass. & NEWARK, Del.--(BUSINESS WIRE)---- $WAT #UDel--Waters Corporation opens Immerse Delaware, an innovation and research laboratory to address significant challenges in the biopharmaceutical industry.

Waters and University of Delaware Announce Official Opening of Immerse Delaware Lab

Waters Corp (NYSE: WAT) reported first-quarter FY22 revenue growth of 16% year-on-year in CC to $690.6 million, above the consensus of $632.8 million. Sales into the pharmaceutical market increased 19% in CC, sales into the industrial market increased 17% in CC, and sales into the.

Why Waters Corp Shares Are Surging Today

Waters' (WAT) first-quarter results reflect gains from a strong momentum across pharmaceutical and industrial end-markets, and geographical regions.

Waters (WAT) Q1 Earnings Surpass Estimates, Sales Rise Y/Y

Waters Corporation (NYSE:WAT ) Q1 2022 Earnings Conference Call May 3, 2022 8:00 AM ET Company Participants Caspar Tudor - Manager of Investor Relations Udit Batra - President & Chief Executive Officer Amol Chaubal - Senior Vice President & Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Rachel Vatnsdal - JPMorgan Dan Brennan - Cowen & Company Josh Waldman - Cleveland Research Puneet Souda - SVB Securities Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Dan Arias - Stifel Operator Good morning and welcome to the Waters Corporation First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode until the question-and-answer session of today's call.

Waters Corporation (WAT) CEO Udit Batra on Q1 2022 Results - Earnings Call Transcript

Waters (WAT) delivered earnings and revenue surprises of 20.69% and 9.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Waters (WAT) Q1 Earnings and Revenues Beat Estimates

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) today announced its financial results for the first quarter of 2022. “Our teams continue to deliver excellent results despite the challenging environment. This was a record first quarter for Waters' sales, led by instruments which grew 26% in constant currency, while our recurring revenues grew 9% in constant currency, reflecting continued demand across our geographies and end-markets,” said Dr. Udit Batra, President and Chief Exec

Waters Corporation (NYSE: WAT) Reports First Quarter 2022 Financial Results

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) announced today that it will host its 2022 Investor Day on Thursday, May 19, 2022, starting at 8:45 a.m. (ET) at the New York Stock Exchange, 11 Wall St, New York, NY 10005. The event will feature presentations made by members of the senior management team, followed by a Q&A session. A live webcast of the presentation will be available on Waters' investor relations website, https://ir.waters.com. A replay of the webcast will als

Waters Corporation to Host Investor Day

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) will webcast its Q1 2022 financial results conference call live on Tuesday, May 3rd 2022 at 8:00 a.m. eastern time. A live webcast of the presentation will be available on Waters' investor relations website at https://ir.waters.com. A replay of the webcast will also be available until at least May 17th 2022 at midnight eastern time. About Waters Corporation Waters Corporation (NYSE:WAT), the world's leading specialty measurement com

Waters Corporation Q1 2022 Financial Results Webcast Invitation

Waters (WAT) unveils the Xevo TQ Absolute system, which is up to 15 times more sensitive, 45% smaller in size, and consumes up to 50% less electricity and gas supply.

Waters (WAT) Expands Portfolio With Xevo TQ Absolute System

MILFORD, Mass.--(BUSINESS WIRE)-- #bioanalysis--Waters introduces the Xevo TQ Absolute, the most sensitive and compact tandem quadrupole mass spectrometer in its class.

Waters Introduces Xevo TQ Absolute – The Most Sensitive and Compact Benchtop Tandem Quadrupole Mass Spectrometer

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Waters (WAT) is a Strong Momentum Stock

Waters (WAT) introduces the Intact Mass Software application on waters_connect and Waters MaxPeak Premier Protein BEH C4 300A Columns for biomolecule drug discovery and development.

Waters (WAT) Boosts Its LC-MS Efforts With Latest Software

MILFORD, Mass.--(BUSINESS WIRE)-- #biologics--Waters Corporation introduces new software and analytical columns to aid biomolecule drug discovery and development.

Waters Introduces Faster, Reliable and Automated Solution for Mass and Purity Analysis of Biomolecules

Why Is Waters (WAT) Down 4.4% Since Last Earnings Report?

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Cowen Healthcare Conference on Wednesday, March 9th, 2022 at 2:10PM Eastern Standard Time. Interested investors can access the live webcast of the presentation on Waters' investor relations website at https://ir.waters.com. A replay of the webcast will be available for 30 days. About Waters Corporation Waters Corporation (NYSE:WAT), t

Waters Corporation Presentation at the Cowen 42nd Annual Health Care Conference

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) Amol Chaubal, SVP & Chief Financial Officer will participate in a virtual fireside chat at Citi's 2022 Virtual Healthcare Conference on Thursday, February 24th at 3:30PM Eastern Time. Interested investors can access the live webcast of the presentation on Waters' investor relations website at https://ir.waters.com. A replay of the webcast will be available for 30 days. About Waters Corporation Waters Corporation (NYSE:WAT), the

Waters Corporation Virtual Fireside Chat at Citi's 2022 Virtual Healthcare Conference (including: Services, MedTech, Life Science Tools & HCIT)

Abbott Labs

Alnylam Pharmaceuticals

Bristol-Myers

Cerner

Regeneron Pharmaceuticals

Stryker

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.

The Vanguard Health Care Fund's Top 5 Trades

Waters' (WAT) fourth-quarter results reflect gains from a strong momentum across end-markets and geographical regions.

Waters (WAT) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

Waters Corporation (WAT) CEO Udit Batra on Q4 2021 Results - Earnings Call Transcript

News for Waters Stock (WAT)